The transient receptor potential TRPV1 or vanilloid receptor is a nonselective ligand-gated channel highly expressed in primary sensory neurons where it mediates nociception. TRPV1 is also expressed in the brain where its activation depresses excitatory synaptic transmission. Whether TRPV1 also regulates inhibitory synapses in the brain is unclear. Here, using a combination of pharmacology, electrophysiology, and an in vivo knockdown strategy, we report that TRPV1 activation by capsaicin or by the endocannabinoid anandamide depresses somatic, but not dendritic inhibitory transmission in both rat and mouse dentate gyrus. The effect on somatic inhibition was absent in TRPV1 knock-out mice and was also eliminated by two different TRPV1 shRNAs expressed in dentate granule cells, strongly supporting a functional role for TRPV1 in modulating GABAergic synaptic function. Moreover, TRPV1-mediated depression occurs independently of GABA release, requires postsynaptic Ca 2ϩ rise and activation of calcineurin, and is likely due to clathrin-dependent internalization of GABA receptors. Altogether, these findings reveal a novel form of compartment-specific regulation whereby TRPV1 channels can modify synaptic function in the brain.
Introduction
TRPV1, also known as VR-1 for vanilloid receptor type-1 (Caterina et al., 1997) , is a nonselective, ligand-gated cation channel that can be activated by a variety of noxious, physical, and chemical stimuli, including endogenous lipid ligands such as the endocannabinoid (eCB) anandamide (AEA; Ross, 2003) . These channels have been well characterized at afferent peripheral sensory neurons, where their activation regulates synaptic transmission associated with pain sensation (Caterina and Julius, 2001) . Increasing anatomical, functional, and behavioral evidence supports the presence of functional TRPV1 channels also in the CNS (Sasamura et al., 1998; Mezey et al., 2000; Huang et al., 2002 Huang et al., , 2014 Marinelli et al., 2003; D.P. Li et al., 2004; Roberts et al., 2004; Tó th et al., 2005; Cristino et al., 2006; Marsch et al., 2007; Gibson et al., 2008; H.B. Li et al., 2008; Maccarrone et al., 2008; Aguiar et al., 2009; Maione et al., 2009; Musella et al., 2009 Musella et al., , 2010 Chávez et al., 2010; Grueter et al., 2010; Bennion et al., 2011; Puente et al., 2011 Puente et al., , 2014 P. Han et al., 2013; Terzian et al., 2014) . Of note, a recent report suggests that TRPV1 channels are restricted to a few brain areas (Cavanaugh et al., 2011) . Thus far, most work in the brain has focused on the role of TRPV1 channels at excitatory synapses where their activation can modify synaptic transmission via both presynaptic (Marinelli et al., 2002 (Marinelli et al., , 2003 Gibson et al., 2008; Musella et al., 2009; Köles et al., 2013) and postsynaptic mechanisms (Chávez et al., 2010; Grueter et al., 2010; Puente et al., 2011; Kim et al., 2012) . However, the role of TRPV1 channels at inhibitory synapses remains poorly understood.
TRPV1 channels can indirectly modulate inhibition by regulating excitatory afferents onto GABAergic interneurons (Derbenev et al., 2006; Ferrini et al., 2007; Zhou et al., 2007; Gibson et al., 2008; Liao et al., 2011) , or by mobilizing eCBs (Maccarrone et al., 2008 ) that suppress GABA release via type-1 cannabinoid receptors (CB1Rs). In the dentate gyrus (DG), a key relay station that controls information transfer from the entorhinal cortex into the hippocampus, inhibitory interneurons make somatic and dendritic synapses onto dentate granule cells (DGCs; Z.S. Han et al., 1993; Hefft and Jonas, 2005; Liu et al., 2014) . GABA release from somatic inhibitory inputs onto DGCs can be modulated by presynaptic CB1Rs (Isokawa and Alger, 2005; Liu et al., 2014) , and anatomical evidence suggests CB1R and TRPV1 colocalize in the DG (Cristino et al., 2006) . It remains unknown whether TRPV1 directly regulates inhibitory transmission and whether CB1Rs act cooperatively to regulate GABAergic synapses in the DG.
Here we sought to determine the role of TRPV1 in GABAergic transmission. Using rat and mouse hippocampal slices, selective pharmacology, TRPV1 knock-out mice, and in vivo knockdown strategies, we report that TRPV1 activation selectively reduces somatic, but not dendritic inputs in a transmitter release-and CB1R-independent manner. This TRPV1-mediated depression of inhibitory synaptic transmission requires postsynaptic Ca 2ϩ rise and calcineurin activation, and it is likely mediated by the internalization of type-A GABA receptors (GABA A R). These results reveal an unexpected form of eCB-mediated regulation of GABAergic transmission along the somatodendritic axis of DGCs.
Materials and Methods
All procedures outlined in this study were approved by the Animal Care and Use Committee of Albert Einstein College of Medicine, in accordance with National Institutes of Health guidelines.
Hippocampal electrophysiology. Acute transverse hippocampal slices (400 m thick), except for AAV-shRNA slices (290 m thick), were prepared from Wistar or Sprague Dawley rats, postnatal P15-P32, and C57BL/6 mice (Trpv1
Ϫ/Ϫ : P27-P32), either sex, as previously described (Chávez et al., 2010; Rodenas-Ruano et al., 2012) . Briefly, the hippocampi were isolated and cut in a solution containing the following (in mM): 215 sucrose, 2.5 KCl, 26 NaHCO 3 , 1.6 NaH 2 PO 4 , 1 CaCl 2 , 4 MgCl 2 , 4 MgSO 4 , and 20 glucose. Thirty minutes post sectioning, slices were incubated in extracellular ACSF recording solution containing the following (in mM): 124 NaCl, 2.5 KCl, 26 NaHCO 3 , 1 NaH 2 PO 4 , 2.5 CaCl 2 , 1.3 MgSO 4 , and 10 glucose. All solutions were equilibrated with 95% O 2 and 5% CO 2 , pH 7.4.
Hippocampal slices were visualized using infrared DIC and nontargeting GFP-control and Trpv1-shRNA DGCs were visualized using fluorescence video microscopy on a Nikon eclipse E600FN microscope ( Fig.  2A) . All experiments, except where indicated, were performed at 28 Ϯ 1°C in a submersion-type recording chamber perfused at ϳ1-2 ml/min with ACSF supplemented with 10 M NBQX and 25 M D-APV to block AMPA and NMDA receptors, respectively. Whole-cell patch-clamp recordings using a Multiclamp 700A amplifier (Molecular Devices) were made from DGCs voltage-clamped at ϩ5 mV, unless otherwise stated, using patch-type pipette electrodes (ϳ3-4 M⍀) containing the following (in mM): 131 Cs-gluconate, 8 NaCl, 1 CaCl 2 , 10 EGTA, 10 glucose, and 10 HEPES; pH 7.4, 285-292 mmol/kg. All recordings were performed from DGCs whose somas were Ͻ30 m from the molecular layer. For BAPTA experiments (Fig. 5A ), 20 mM cesium gluconate, 10 mM EGTA, and 1 mM CaCl 2 were replaced with 20 mM BAPTA (osmolarity and pH adjusted with CsOH). To isolate excitatory responses (Fig. 4C ), NBQX and D-APV were replaced with 100 M picrotoxin (PTX) to block GABA A Rs and DGCs were voltage clamped at Ϫ60 mV. Series resistance (ϳ10 -25 M⍀) was monitored throughout all experiments with a Ϫ5 mV, 80 ms voltage step, and cells that exhibited significant change in series resistance (Ͼ20%) were excluded from analysis. To differentially stimulate inhibitory synaptic inputs, two monopolar-stimulating patchtype pipettes were filled with ACSF and placed in the dentate granule layer (DGL; Ͻ20 m from the border with the molecular layer) to activate somatic inputs, and in the middle third of the molecular layer (MML) to stimulate dendritic inputs. Somatic extracellular field inhibitory synaptic potentials (fIPSPs) were recorded using pipettes filled with 1 M NaCl while the stimulating pipette was placed in the DGL. Stimulation intensity was adjusted to produce 0.2-0.4 mV fIPSP amplitude. Exogenous GABA responses (Fig. 3C) were evoked by directly puffing GABA (1 mM, 25 ms, 2 psi) using a Picospritzer III (Parker) connected to a patch pipette (resistance, 3-4 m⍀). The tip of the puffer pipette was positioned close to the recorded cell in the DGL or in the MML ϳ30 M deep from the surface of the slice. All experiments and analyses using Trpv1 Ϫ/Ϫ and CB1R Ϫ/Ϫ mice were performed in a blind fashion. Except where indicated, pharmacological agents were bath applied after a stable baseline was established (ϳ10 -15 min), and their effects were measured after responses reached a new steady state (typically Ͼ15 min). Stock solutions were prepared in water or DMSO and added to the ACSF as needed. Total DMSO in the ACSF was maintained at Ͻ0.1%. Drugs were obtained from Sigma and Tocris Bioscience, except WIN55, 212-2, D-APV, and NBQX, which were obtained from the NIMH Chemical Synthesis and Drug Supply Program. IPSCs were elicited every 20 s, filtered at 2.4 kHz, and acquired at 5 kHz using a custom-made software written in Igor Pro 4.09A (WaveMetrics). Statistical comparisons were made using paired and unpaired two-tailed Student's t test and ANOVA at the p Ͻ 0.05 significance level in OriginPro 7.0 and 8.6 (OriginLab). Unless otherwise indicated, all values are provided as the mean Ϯ SEM and illustrated traces are averages of 31-35 responses.
AAV-shRNA design and cloning. Trpv1 shRNA-1 (sense: GGCCAG-GUAACUCUUACAACAGC) and TrpV1 shRNA-2 (sense: CGCUU-GUAUAUGAUCAUCUUCA) with complete complementarity to the coding region of mouse (NM_001001445) and rat (NM_031982) sequences, and a nontargeting control shRNA (GAGGAUCAAAUU-GAUAGUAAACC) with no sequence homology to any known gene transcript were designed. Desalted shRNA oligos containing a modified miR155 loop (GTTTTGGCCACTGACTGAC) and overhangs complementary to BamHI and XhoI restriction sites were custom synthesized (Invitrogen), annealed, and cloned into a "CreOff" AAV vector with a floxed cassette that comprises a U6 polymerase III promoter to drive shRNA expression, a CMV promoter to drive eGFP expression (Ventura et al., 2004) for identification of transduced neurons, and a woodchuck post-transcriptional response element to promote transgene expression. AAVs with serotype 9 were subsequently produced by Virovek using a baculovirus expression system (Chen, 2008) .
qRT-PCR and stereotaxic injection of Trpv1 AAV-shRNA constructs. For qRT-PCR, GFP
ϩ DGCs were suctioned with a patch pipette from acute slices and RNA was extracted by means of the Dynabeads mRNA direct micro kit (Invitrogen). Real-time quantitative qPCR was performed with TaqMan probes (Applied Biosystems) for Trpv1 (Rn00583117) and hypoxanthine phosphoribosyltransferase; RN01527838_g1 (Hprt). Reactions were run in triplicate in a StepOnePlus real-time PCR system (Applied Biosystems). mRNA abundance was calculated by means of the comparative cycle threshold method at a threshold of 0.02. Data were analyzed using the software tool REST (http://www.REST.de.com/), on the basis of the group mean for the target transcript, versus reference Hprt transcript or Gapdh transcript.
For in vivo experiments Trpv1-shRNA was delivered by stereotaxic injection into the DG of live rats at P10 (Rodenas-Ruano et al., 2012) and all recorded neurons were assessed at P28 -P35. Rats were placed in a stereotaxic frame and anesthetized with isoflurane and concentrated viral solution (2 l) was injected into the right DG (3.4 mm posterior to bregma, 3.2 mm lateral to bregma, and 3.1 mm ventral from dura) at a flow rate of 0.2 l/min.
Results

TRPV1 activation selectively depresses somatic inhibition onto DGCs
To evaluate the role of TRPV1 on GABAergic inputs onto DGCs, putative somatic and dendritic IPSCs were monitored from the same cell (see Materials and Methods), and TRPV1 channels were activated with the specific agonist capsaicin (CAP; 2 M). We found that CAP bath application selectively depressed somatic, but not dendritic IPSCs in rat (Somatic: 62.6 Ϯ 4.07% of baseline, n ϭ 8, p Ͻ 0.001 paired t-test; Dendritic: 94.7 Ϯ 2.7% of baseline, n ϭ 8, p Ͼ 0.05 paired t-test; Fig. 1A ). Subsequent application of the GABA A Rs antagonist PTX (100 M) eliminated the CAPinsensitive component (Fig. 1A) . CAP also depressed less invasive, PTX-sensitive, extracellular fIPSPs recorded in DGL (see Materials and Methods; fIPSP: 74.1 Ϯ 2.9% of baseline, n ϭ 8, p Ͻ 0.001 paired t-test; Fig. 1B ). Pretreating slices (ϳ10 -20 min) with two different TRPV1 antagonists, capsazepine (CPZ, 10 M) or AMG9810 (AMG, 3 M), eliminated CAP-mediated effects on somatic IPSCs compared with interleaved control slices (Control: 66.7 Ϯ 3.7% of baseline, n ϭ 6 vs CPZ: 94.5 Ϯ 1.4% of baseline, n ϭ 7, p Ͻ 0.001 ANOVA and AMG: 95.2 Ϯ 1.6% of baseline, n ϭ 9, p Ͻ 0.001 ANOVA; Fig. 1C ). Moreover, this CAP-mediated effect on somatic inhibition was absent in slices from TRPV1 knock-out mice (Trpv1 ϩ/ϩ : 56.9 Ϯ 2.4% of baseline, 3 animals, 8 cells; Trpv1 Ϫ/Ϫ : 90.1 Ϯ 2.0% of baseline, 3 animals, 7 cells, p Ͻ 0.001 ANOVA; Fig. 1D ). Finally, transient TRPV1 activation with CAP (for 10 min), chased with CPZ, induced a long-lasting suppression of somatic inhibitory transmission (74.7 Ϯ 4.5% of baseline; n ϭ 6, p Ͻ 0.005, paired t-test; Fig. 1E ). These results indicate that in DG, TRPV1 channels can suppress GABAergic synaptic transmission in a compartment-specific and longlasting manner.
TRPV1-mediated effects are CB1 receptor independent and likely postsynaptic in nature
We next investigated the mechanism by which TRPV1 activation depresses somatic GABAergic transmission. One possibility is that TRPV1 could indirectly depress somatic GABA release by mobilizing eCBs that activate presynaptic CB1Rs (Maccarrone et al., 2008) . However, CB1R blockade with AM251 (4 M) had no effect on the CAP-mediated depression of somatic IPSCs (to 60.1 Ϯ 3.0% of baseline, n ϭ 6, p Ͻ 0.001 paired t-test; Fig. 2A ), whereas in interleaved experiments, AM251 abolished the depression of GABAergic transmission induced by the CB1R agonist WIN55, 212-2 (5 M; WIN: 50.2 Ϯ 4.0 of baseline, n ϭ 8 vs WIN ϩ AM251: 90.6 Ϯ 3.4 of baseline, n ϭ 4, p Ͻ 0.001 ANOVA; Fig. 2A ). In addition, CAP-mediated depression was observed in both wild-type and CB1R knock-out mice (CB1R ϩ/ϩ : 75.5 Ϯ 3.8% of baseline, n ϭ 6; CB1 Ϫ/Ϫ : 64.4 Ϯ 2.1% of baseline, n ϭ 7; Fig. 2B ). Moreover, activation of TRPV1 channels with the eCB AEA (30 M), in the presence of the fatty acid amide hydrolase (FAAH) inhibitor URB597 (1 M) to block AEA degradation, and the CB1R antagonist AM251 (4 M), selectively depressed somatic, but not dendritic IPSCs (Somatic: 65.9 Ϯ 3.2% of baseline, n ϭ 10, p Ͻ 0.001 paired t-test; Dendritic: 97.8 Ϯ 2.5% of baseline, n ϭ 10, p ϭ 0.356 paired t-test; Fig. 2C ). This AEA-mediated depression was eliminated by two TRPV1 antagonists AMG (100.0 Ϯ 3.8% of baseline, n ϭ 6, p ϭ 0.799 paired t-test) or CPZ (95.1 Ϯ 2.7% of baseline, n ϭ 3, p ϭ 0.220 paired t-test; Fig. 2C ). These results strongly argue that TRPV1-mediated depression of GABAergic transmission is CB1R independent.
To determine whether TRPV1 channels could directly depress GABA release, we examined the effects of CAP on both paired-pulse ratio (PPR; Fig. 3 A, B) and coefficient of variation (1/CV 2 ; Fig. 3A ), two different measures that estimate changes in probability of release. Unlike WIN-mediated depression of inhibition (Fig. 3A) , AEA-and CAP-mediated depression were not accompanied by significant changes in either PPR (Fig. 3 A, B ) or 1/CV 2 (Fig. 3A) in both rat and mouse DG. It is therefore unlikely that a reduction in GABA release underlies AEAand CAP-mediated effects on inhibitory transmission. To directly test whether TRPV1 channels could act postsynaptically, we monitored GABAergic responses elicited by brief puffs of GABA (1 mM), a manipulation that shortcuts transmitter release. GABA-evoked responses (monitored at 0 mV) elicited by puffing in DGL (i.e., DGC soma), but not in MML (i.e., DGC dendrites), were significantly depressed by 2 M CAP (soma: 64.07 Ϯ 2.6% of baseline, n ϭ 5, p Ͻ 0.001 paired t-test; dendrites: 100.47 Ϯ 3.3% of baseline, n ϭ 5, p ϭ 0.890 paired t-test; Fig. 3C ). At the end of each experiment, we confirmed that these responses were blocked by 100 M PTX (Fig. 3C) . These results indicate that TRPV1 channels depress inhibitory synaptic transmission postsynaptically rather than by reducing GABA release.
In vivo knockdown of TRPV1 eliminates TRPV1-mediated effects on synaptic transmission As a complementary approach to TRPV1 pharmacology, we used two different RNA interferences targeted to different Trpv1 regions to knockdown TRPV1 in DGCs. We stereotaxically injected synthetic shRNA targeted to TRPV1 (Trpv1 shRNA-1 and Trpv1 shRNA-2) or nontargeting shRNA directly into the rat DG ( Fig. 4A ; see Materials and Methods). Two to three weeks post injections, we validated the efficacy of the TRPV1 knockdown by suctioning DGCs from hippocampal slices using a patch-type pipette and obtaining samples enriched with GFP ϩ -expressing neurons. Despite the presence of GFP Ϫ cells in our sample, qRT-PCR analysis revealed that the levels of Trpv1 mRNA in DGCs were significantly reduced by both Trpv1 shRNA-1 and Trpv1 shRNA-2 relative to nontransduced control cells (Trpv1 shRNA-1: 40 Ϯ 9.0% of control, three animals, p ϭ 0.008, Trpv1 shRNA-2: 55.8 Ϯ 6.5% of control, 6 animals, p ϭ 0.001; see Materials and Methods; Fig. 4B ). To assess the functional impact of knocking down TRPV1 in DGCs, we first examined excitatory synaptic inputs (i.e., MPP synapses) where we previously reported that TRPV1 activation suppresses transmission (Chávez et al., 2010) . We found that CAP-mediated depression of AMPARs-EPSCs was similar between nontargeting shRNA and nontransduced neurons and thus, these neurons were pooled for further analysis (9 nontargeting vs 10 nontransduced cells; p ϭ 0.98 ANOVA; Fig. 4C ). In contrast, the CAPmediated depression was significantly reduced in neurons expressing Trpv1 shRNA-1 (94.6 Ϯ 3.0% of baseline, 5 animals/9 cells; Fig. 4C ) or Trpv1 shRNA-2 (93.7 Ϯ 4.9% of baseline, 4 animals/10 cells; Fig. 4C ) when compared with control neurons (60.2 Ϯ 3.2% of baseline, 9 animals/19 cells; Control vs Trpv1 shRNA-1 or Trpv2 shRNA-2, p Ͻ 0.001, ANOVA; Fig. 4C ). Importantly, we also found that CAP-mediated depression of GABAergic transmission was reduced in neurons expressing Trpv1 shRNA-1 (83.4 Ϯ 4.6% of baseline, 6 animals/13 cells) and Trpv1 shRNA-2 (88.7 Ϯ 3.0% of baseline, 6 animals/12 cells) when compared with nontransduced control neurons recorded in interleaved experiments (control: 51.2 Ϯ 6.8% of baseline, 5 animals/6 cells; shRNA-1 vs Control p ϭ 0.001 ANOVA; shRNA-2 vs Control p Ͻ 0.001, ANOVA; Fig. 4D ). Thus, our findings using complementary TRPV1 knockdown (Fig. 4) and selective pharmacology (Figs. 1-3 ) demonstrate that activation of TRPV1 channels in DGCs depresses both excitatory and inhibitory transmission by regulating postsynaptic AMPA and GABA receptors, respectively. 2 of somatic IPSCs. These results were generated from the experiments reported in Figure 1A and D and Figure 2A and C. B, CAP did not alter PPR of fIPSPs recorded as in Figure 1B and measured at different interstimulus intervals (10, 30, 75, 100, and 300 ms). fIPSPs were normalized to the first response. C, Representative traces (left) and summary plot (right) showing that CAP also mediated depression of GABAR-mediated responses evoked by puffing GABA (1 mM, 25 ms) in the DGL (somatic) but not in the middle third of the molecular layer (dendritic). Subsequent application of PTX (100 M) eliminated the CAP-insensitive component of GABA-evoked responses. In all cases, averaged sample traces taken at times indicated by numbers are shown next to each summary plot. Summary data represent the mean Ϯ SEM. **p Ͻ 0.01. Grueter et al., 2010 Fig. 5A ). In addition, pretreatment of slices with 30 M cyclopiazonic acid (CPA), a manipulation aimed to deplete intracellular Ca 2ϩ stores, significantly reduced CAP-mediated depression of somatic IPSCs compared with interleaved control neurons (CPA: 80.1 Ϯ 1.7%, n ϭ 11, CPA vs Control: p Ͻ 0.001 ANOVA; Fig. 5A ). In interleaved experiments, CPA did not affect basal synaptic transmission (98.7 Ϯ 8.1% of control, n ϭ 4, p ϭ 0.898 paired t test; Fig. 5A, bottom) . Next, we tested whether the Ca 2ϩ / calmodulin-dependent protein phosphatase calcineurin (CaN) could also participate in the TRPV1-mediated suppression of GABAergic transmission, as we previously reported at excitatory synapses in the DG (Chávez et al., 2010) . Pretreatment of slices for 30 min with CaN inhibitors, FK506 (50 M) and Cyclosporin A (CyA; 25 M) eliminated CAP-mediated depression of GABAergic transmission compared with control slices (Control: 62.6 Ϯ 2.5% of baseline, n ϭ 9 vs FK506: 92.0 Ϯ 3.5% of baseline, n ϭ 7, p Ͻ 0.001 ANOVA; CyA: 94.0 Ϯ 3.0% of baseline, n ϭ 7, p Ͻ 0.001 ANOVA; Fig. 5B ). Application of FK506 and CyA for 30 min did not affect basal synaptic transmission (FK506: 98.6 Ϯ 3.7% of baseline, n ϭ 6, p ϭ 0.538, paired t test; CyA: to 100.5 Ϯ 6.1% of baseline, n ϭ 7, p ϭ 0.998, paired t test; Fig.  5B, bottom) . Finally, we investigated whether dynamin-dependent endocytosis of GABA A Rs could be involved in the TRPV1-mediated depression of inhibitory transmission. To test this possibility, we loaded DGCs with the dynamin inhibitory peptide (DIP; 50 M), and found that this peptide significantly reduced CAP-mediated depression of inhibition compared with a scrambled DIP (DIP: 92.7 Ϯ 4.9% of baseline, n ϭ 10 vs scrambled DIP: 59.3 Ϯ 6.5% of baseline, n ϭ 7, p Ͻ 0.001, ANOVA; Fig. 5D ). Thus, our results strongly suggest that activation of TRPV1 channels leads to an increase in postsynaptic Ca 2ϩ rise which, by activating the CaN-dynamin complex, likely promotes GABA A Rs endocytosis.
Mechanisms underlying TRPV1-mediated suppression of inhibition
Discussion
The results presented in this study demonstrate that TRPV1 channels, in addition to modulating excitatory synaptic inputs (Chávez et al., 2010; Grueter et al., 2010; Puente et al., 2011) , can also target inhibitory synapses in rat and mouse DG. We report that activation of TRPV1 channels, presumably by promoting internalization of GABA A Rs, selectively depresses somatic but not dendritic GABAergic synaptic inputs onto DGCs. We also show that the eCB AEA depresses inhibitory synaptic transmission by targeting TRPV1 channels, and this effect can occur while CB1Rs are pharmacologically blocked. To our knowledge, we provide the first evidence that TRPV1 channels can directly regulate inhibitory transmission at central synapses.
In the CNS, there is good evidence that activation of TRPV1 channels regulates excitatory transmission either presynaptically by modulating glutamate release (for review, see Kauer and Gibson, 2009) , or postsynaptically by promoting AMPAR removal from the synapse (Chávez et al., 2010; Grueter et al., 2010; Kim et al., 2012) . In contrast, previous attempts have not identified any effect of TRPV1 activation on synaptic inhibition (Yang et al., 1998; Marinelli et al., 2003; D.P. Li et al., 2004; Xing and Li, 2007) . Our finding that TRPV1 channels suppress somatic but not dendritic inhibitory inputs (Figs. 1, 2) is reminiscent of previous observations showing that the TRPV1-mediated depression of excitatory transmission occurs at some synaptic inputs but not others (Chávez et al., 2010; Grueter et al., 2010; Puente et al., 2011) . Thus, input specificity could be a general property of TRPV1-mediated effects throughout the brain.
The precise mechanism underlying input specificity of TRPV1-mediated suppression of synaptic transmission is unclear. For example, it could reflect the selective expression of TRPV1 channels at some synapses, although spatially constrained signaling downstream of TRPV1 channels may also contribute. In support of TRPV1 synaptic segregation, a recent anatomical immunoelectron microscopy study in DG showed that TRPV1 is highly concentrated in postsynaptic dendritic spines receiving perforant path inputs, whereas expression is weak at more proximal excitatory hilar mossy cell synapses (Puente et al., 2014) . This subcellular anatomical distribution is consistent with the selective TRPV1-mediated suppression of excitatory transmission at medial perforant path but not hilar mossy cell synapses (Chávez et al., 2010). GABAergic interneurons in the DG comprise a diverse group of cell types (Houser, 2007) with domain-specific innervation and distinct functional properties (Z.S. Han et al., 1993; Hefft and Jonas, 2005; Liu et al., 2014) , raising the possibility that TRPV1 channels also could be expressed at subtypes of inhibitory synapses. Regardless of the precise synapse type, by selectively suppressing somatic inhibition, TRPV1 channels may control DGC spike initiation (Miles et al., 1996) . The fact that TRPV1 channels modulate both excitatory (Chávez et al., 2010) and inhibitory transmission in a compartment-specific manner indicates that TRPV1 might play a subtle role in regulating synaptic integration and DGC output. While exogenous activation of TRPV1 channels is expected to suppress both excitatory and inhibitory inputs onto DGCs, it remains to be seen whether both actions can occur simultaneously by endogenous TRPV1 activation.
TRPV1 can be activated by lipid messengers such as the eCB AEA (Ross, 2003) . Typically, eCBs are mobilized from the postsynaptic compartment and act retrogradely to suppress transmitter release by activating presynaptic CB1Rs (Kano et al., 2009; , and in most synapses, this form of retrograde signaling is likely mediated by the eCB 2-AG (OhnoShosaku and Kano, 2014). Growing evidence, however, indicates that eCBs can also regulate synaptic function in an unconventional manner by activating postsynaptic TRPV1 channels . Our findings that AEA regulates GABAergic transmission in a postsynaptic and CB1R-independent manner provide further support for this way of regulating synaptic function via eCBs. Previous work in the DG showed that retrograde eCB signaling suppresses GABA release (Isokawa and Alger, 2005) , suggesting eCB-mediated modulation of synaptic inhibition is complex. In addition, AEA acting on TRPV1 channels could facilitate 2-AG production and by this means suppress synaptic inhibition via CB1Rs, as previously reported in dorsal striatum (Maccarrone et al., 2008) . However, we show that AEA in the DG suppresses GABAergic transmission in a CB1R-independent manner by activating TRPV1 channels. It has recently been reported that specific patterns of activity mobilizes AEA or 2-AG from the same neuron and, by activating postsynaptic TRPV1 channels or presynaptic CB1Rs, respectively, these eCBs trigger mechanistically different forms of long-term depression (LTD) at excitatory synapses (Grueter et al., 2010; Puente et al., 2011) . Whether endogenous activation of TRPV1 and CB1Rs can trigger similar forms of long-term plasticity at inhibitory synapses remains to be determined.
Recent studies have shown that activation of TRPV1 channels promotes AMPAR internalization at excitatory synapses in the DG (Chávez et al., 2010) , nucleus accumbens (Grueter et al., 2010) , and spinal cord (Kim et al., 2012) . In the DG, we have reported that TRPV1-mediated endocytosis of AMPARs occurs in a CaN/dynamin-dependent manner (Chávez et al., 2010) , and our new findings indicate that this mechanism also operates for GABA A Rs (Fig. 5) . Notably, CaN has been involved in TRPV1-mediated downregulation of voltage-gated Ca 2ϩ channels in primary sensory neurons (Wu et al., 2005) and TRPV1-induced LTD in hippocampal interneurons (Jensen and Edwards, 2012) . Together, these observations substantiate the notion that CaN is a common downstream target of TRPV1-mediated effects.
In summary, our data provide further evidence in support of functional TRPV1 channels as regulators of synaptic transmission in the CNS. Such regulation, at least in DG, is input specific, includes excitatory and inhibitory synapses, and could play a role in controlling the relative weight of excitatory and inhibitory inputs. Although our understanding of brain TRPV1 in vivo is currently rather limited, studies using TRPV1 knock-out mice suggest that this channel might be involved in drug addiction (Grueter et al., 2010) , anxiety, and fear condition (Marsch et al., 2007) . In addition, TRPV1 protein levels are reportedly increased in the DG of an animal model of epilepsy (Bhaskaran and Smith, 2010) , suggesting that TRPV1 could be regulated by aberrant neural activity. Brain TRPV1-mediated actions deserve attention given that TRPV1 antagonism has emerged as an alternative strategy for pain management. Additional work is necessary to fully understand under what conditions TRPV1 modulates excitatory and inhibitory inputs and ultimately, to determine how exactly modulation of these inputs affects brain function.
